AbbVie | ABBV - Ebit


AbbVie reported $6.88B in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Abbott USD 1.36B 775M Sep/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eisai JPY 16.7B 8.03B Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
J&J USD 6.47B 1B Sep/2026
Medtronic USD 1.84B 254M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 411M Sep/2026
Pacira USD 2.57B 2.56B Sep/2026
Perrigo USD 27.2M 116.6M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
UCB EUR 1.29B 571M Dec/2025
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
United Therapeutics USD 241.3M 134.3M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026
Zoetis USD 1.03B 88M Sep/2026